Management of Shortness of Breath with Brilinta (Ticagrelor)

Understanding Ticagrelor-Associated Dyspnea

The American College of Cardiology notes that ticagrelor causes dyspnea in approximately 10-15% of patients through adenosine-mediated mechanisms, with symptoms typically being mild to moderate in severity 1
Dyspnea associated with ticagrelor usually occurs within the first week of therapy and is self-limited, often resolving without intervention 2
The European Society of Cardiology guidelines indicate that ticagrelor-associated dyspnea is not associated with objective pulmonary function abnormalities 1

The American Heart Association recommends ruling out life-threatening conditions, such as pulmonary embolism, acute coronary syndrome, anaphylaxis, and heart failure exacerbation, before attributing dyspnea solely to ticagrelor 2
Assessment for pulmonary embolism should include evaluation of chest pain, hemoptysis, unilateral leg swelling, tachycardia, and vital signs with oxygen saturation 2
Evaluation for acute coronary syndrome should consider ongoing cardiac ischemia, especially given the indication for antiplatelet therapy 3

The European Respiratory Society suggests performing objective testing, such as baseline spirometry, to rule out asthma, COPD, or restrictive lung disease 1
Measurement of BNP/NT-proBNP is recommended if orthopnea or heart failure signs are present, with a BNP <100 pg/mL having 96-99% sensitivity for ruling out heart failure 2
A focused physical examination should be conducted to evaluate cardiac and pulmonary findings 2

The American College of Cardiology recommends continuing ticagrelor and providing reassurance that drug-associated dyspnea is typically benign and self-limited, with monitoring of symptoms over 2-4 weeks 1
If an underlying respiratory disease is diagnosed, treatment of the identified condition should be initiated while continuing ticagrelor 2
For cardiac etiologies, optimization of heart failure management with guideline-directed medical therapy is essential 3
Low-dose oral morphine may be considered for chronic breathlessness in heart failure patients, with 63% of patients responding to morphine and 67% of responders benefiting at 10 mg/day 3

The European Society of Cardiology recommends scheduling reassessment within 2-4 weeks to evaluate symptom trajectory, response to initiated therapies, and need for specialist referral 1
Consideration of alternative antiplatelet therapy may be necessary if dyspnea remains severe and disabling despite negative workup 3